|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013030,
umls-concept:C0030685,
umls-concept:C0031268,
umls-concept:C0032743,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0072953,
umls-concept:C0243076,
umls-concept:C0391871,
umls-concept:C0528200,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1415809,
umls-concept:C1708300,
umls-concept:C1709059,
umls-concept:C1963578,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-9-26
|
|
pubmed:abstractText |
Antagonism at serotonin 5-HT2A and 5-HT2C receptors modulates cortical and striatal dopamine (DA) release and may underlie some aspects of the clinical efficacy of 'atypical' antipsychotic compounds. However, it is not known whether 5-HT2A/2C receptor-mediated modulation of DA release can be quantified with non-invasive neurochemical imaging, as would be required for investigation of these processes in man.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amphetamine,
http://linkedlifedata.com/resource/pubmed/chemical/Carbon Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Ketanserin,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Raclopride,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2,
http://linkedlifedata.com/resource/pubmed/chemical/SB 206553,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin 5-HT2 Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Antagonists
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0033-3158
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
200
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
487-96
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18597077-Amphetamine,
pubmed-meshheading:18597077-Animals,
pubmed-meshheading:18597077-Binding, Competitive,
pubmed-meshheading:18597077-Carbon Radioisotopes,
pubmed-meshheading:18597077-Corpus Striatum,
pubmed-meshheading:18597077-Dopamine,
pubmed-meshheading:18597077-Dopamine Antagonists,
pubmed-meshheading:18597077-Indoles,
pubmed-meshheading:18597077-Ketanserin,
pubmed-meshheading:18597077-Male,
pubmed-meshheading:18597077-Positron-Emission Tomography,
pubmed-meshheading:18597077-Protein Binding,
pubmed-meshheading:18597077-Pyridines,
pubmed-meshheading:18597077-Raclopride,
pubmed-meshheading:18597077-Radiopharmaceuticals,
pubmed-meshheading:18597077-Rats,
pubmed-meshheading:18597077-Rats, Sprague-Dawley,
pubmed-meshheading:18597077-Receptors, Dopamine D2,
pubmed-meshheading:18597077-Serotonin 5-HT2 Receptor Antagonists,
pubmed-meshheading:18597077-Serotonin Antagonists
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.
|
|
pubmed:affiliation |
Division of Neuroscience and Psychological Medicine, Department of Neuroscience and Mental Health, Imperial College London, London, W12 0NN, UK. a.egerton@imperial.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
